| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/30/2009 | US20090110699 Antigen-Adjuvant Compositions and Methods |
| 04/30/2009 | US20090110698 Method of determining vaccine compliance |
| 04/30/2009 | US20090110697 Inactivated bovine herpes virus-1 and methods |
| 04/30/2009 | US20090110696 Mycobacterial SecA2 Mutants |
| 04/30/2009 | US20090110695 Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| 04/30/2009 | US20090110694 Anti-Inflammatory Proteins and Improved Vaccines |
| 04/30/2009 | US20090110693 Multimeric complexes of antigens and an adjuvant |
| 04/30/2009 | US20090110692 Isolated complexes of endotoxin and modified md-2 |
| 04/30/2009 | US20090110691 Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) |
| 04/30/2009 | US20090110690 Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens |
| 04/30/2009 | US20090110689 Immunosuppression compound and treatment method |
| 04/30/2009 | US20090110688 Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
| 04/30/2009 | US20090110687 Compositions and methods related to tim 3, a th1-specific cell surface molecule |
| 04/30/2009 | US20090110686 Antibodies against CCR5 and uses thereof |
| 04/30/2009 | US20090110685 Treatment and prevention of viral infections |
| 04/30/2009 | US20090110684 Neutralizing monoclonal antibodies to respiratory syncytial virus |
| 04/30/2009 | US20090110683 Monoclonal antibodies against activated protein c |
| 04/30/2009 | US20090110682 Antibody Having Inhibitory Effect on Amyloid Fibril Formation |
| 04/30/2009 | US20090110681 Anti-M-CSF Antibody Compositions |
| 04/30/2009 | US20090110680 Combination of an anti ED-B fibronectin domain antibody and gemcitabine |
| 04/30/2009 | US20090110679 Methods and compositions for pulmonary administration of a TNFa inhibitor |
| 04/30/2009 | US20090110678 Receptor antagonists for treatment of metastatic bone cancer |
| 04/30/2009 | US20090110677 Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 04/30/2009 | US20090110676 BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response and Treatment of Autoimmune Disorders |
| 04/30/2009 | US20090110666 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours |
| 04/30/2009 | US20090110662 Modification of biological targeting groups for the treatment of cancer |
| 04/30/2009 | US20090110660 for pancreatic cancer; intravenous infusion; Interleukin-2 (IL-2) |
| 04/30/2009 | US20090110644 Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| 04/30/2009 | US20090110632 Biological materials and uses thereof |
| 04/30/2009 | DE102007050574A1 Lozenge, useful e.g. for preventing cold diseases, comprises colostrum having a concentration of immunoglobulins in concentrated form, glycans as adjuvants, sugar alcohols as entraining agent, a tableting agent and flavoring additives |
| 04/30/2009 | CA2704098A1 Compositions and methods for enhancing immune response |
| 04/30/2009 | CA2703947A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | CA2703738A1 Monoclonal antibodies against activated unactivated protein c |
| 04/30/2009 | CA2703712A1 Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| 04/30/2009 | CA2703668A1 Synthetic antigenic peptides and lipopeptides derived from mycobacterium avium subsp. paratuberculosis |
| 04/30/2009 | CA2703667A1 Anti-rsv g protein antibodies |
| 04/30/2009 | CA2703493A1 A cell for use in production of heteroproteins and production method using the same |
| 04/30/2009 | CA2703489A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | CA2703350A1 Immune response inducer |
| 04/30/2009 | CA2703335A1 Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| 04/30/2009 | CA2703329A1 Use of trkb antibodies for the treatment of respiratory disorders |
| 04/30/2009 | CA2703154A1 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| 04/30/2009 | CA2703140A1 Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| 04/30/2009 | CA2703133A1 Antibody-mediated disruption of quorum sensing in bacteria |
| 04/30/2009 | CA2702984A1 Compositions and methods for treatment of diabetic retinopathy |
| 04/30/2009 | CA2702962A1 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |
| 04/30/2009 | CA2702637A1 Fully human anti-vegf antibodies and methods of using |
| 04/30/2009 | CA2702333A1 Anti-ricin antibody |
| 04/30/2009 | CA2701802A1 Compositions for detecting antibodies to babesia microti and methods of use thereof |
| 04/30/2009 | CA2700430A1 Influenza virus haemagglutinin-specific monoclonal antibodies |
| 04/30/2009 | CA2699805A1 Treatment regime for proliferative disorders |
| 04/30/2009 | CA2695237A1 Anti-rantes antibodies and methods of use thereof |
| 04/30/2009 | CA2672800A1 Human antibodies that bind cd19 and uses thereof |
| 04/29/2009 | EP2053409A1 Specific markers for metabolic syndrome |
| 04/29/2009 | EP2053129A2 Method of diagnosing, monitoring, staging, imaging and treating various cancers |
| 04/29/2009 | EP2053126A1 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 04/29/2009 | EP2053125A1 Streptococcus pyogenes antigens |
| 04/29/2009 | EP2053124A2 Recombinant RSV virus expression systems and vaccines |
| 04/29/2009 | EP2053063A1 Recognition molecules for treatment and detection of tumours |
| 04/29/2009 | EP2053062A1 Immunoglobin variants outside the Fc region |
| 04/29/2009 | EP2053056A1 Dendrimeric peptide construct for the prevention of foot-and-mouth disease in animals |
| 04/29/2009 | EP2052742A1 Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| 04/29/2009 | EP2052737A1 Synthetic antigenic peptides and lipopeptides derived from mycobacterium avium subsp. paratuberculosis |
| 04/29/2009 | EP2052713A2 Soluble FcgammaR fusion proteins and methods of use thereof |
| 04/29/2009 | EP2052253A2 Immunogenic compounds and protein mimics |
| 04/29/2009 | EP2051997A1 Anti-c5ar antibodies with improved properties |
| 04/29/2009 | EP2051734A2 Agents for blood-brain barrier delivery |
| 04/29/2009 | EP2051733A1 A pharmaceutical composition for treating lung cancer, a method for inhibiting growth or invasion of lung cancer and a method for treating lung cancer |
| 04/29/2009 | EP2051710A2 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases |
| 04/29/2009 | EP1558269B1 Botulinum toxin formulations for oral administration |
| 04/29/2009 | EP1461357B1 Novel hev antigenic peptide and methods |
| 04/29/2009 | EP1051494B1 Methods and reagents for decreasing allergic reactions |
| 04/29/2009 | EP0934083B1 Improved vaccines |
| 04/29/2009 | EP0876150B2 Non-toxic mutants of pathogenic gram-negative bacteria |
| 04/29/2009 | EP0835315B1 Vaccine for porcine reproductive and respiratory syndrome virus |
| 04/29/2009 | CN101421395A Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| 04/29/2009 | CN101421304A Affinity regions |
| 04/29/2009 | CN101421303A Improved protofibril selective antibodies and the use thereof |
| 04/29/2009 | CN101421300A Novel sodium channel |
| 04/29/2009 | CN101421299A Peptide vaccine for inducing production of anti-amyloid- -peptide antibody |
| 04/29/2009 | CN101421296A Hypoallergenic chimeric proteins belonging to the lipid transfer family of Parietaria judaica for use in the treatment of allergies |
| 04/29/2009 | CN101420983A Methods and compositions comprising supramolecular constructs |
| 04/29/2009 | CN101420978A Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 04/29/2009 | CN101420977A NOGO receptor antagonists |
| 04/29/2009 | CN101420976A Combination approaches for generating immune responses |
| 04/29/2009 | CN101420975A Vaccine against mycoplasma PRRSV |
| 04/29/2009 | CN101420974A Methods of manufacturing corticosteroid solutions |
| 04/29/2009 | CN101420973A Pharmaceutical compositions comprising SODs and prolamine based peptide fragments |
| 04/29/2009 | CN101420972A Methods for reducing protein aggregation |
| 04/29/2009 | CN101418303A Method for preparing swine fever recombinant subunit vaccine |
| 04/29/2009 | CN101418275A Streptococcus suis type 2 immune protective antigen |
| 04/29/2009 | CN101418045A Immunoglobulin variants and uses thereof |
| 04/29/2009 | CN101418044A Immunoglobulin variants and uses thereof |
| 04/29/2009 | CN101418043A Immunoglobulin variants and uses thereof |
| 04/29/2009 | CN101417128A Preparation of BCG vaccine polysaccharide nucleic acid -DDA adjuvant and use thereof |
| 04/29/2009 | CN100482788C High-yield recombinant influenza B virus strain and its application |
| 04/29/2009 | CN100482688C Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 04/29/2009 | CN100482684C Cytokine protein family |
| 04/29/2009 | CN100482283C Novel chimeric CD154 |
| 04/29/2009 | CN100482281C Method of treatment using anti-ErbB antibody-maytansinoid conjugates |